Press Releases

Creative Enzymes Introduces S-Adenosyl-L-Homocysteine Hydrolase, Recombinant

CD Formulation Provides Efficient Strategies to Develop and Optimize Microspheres & Microneedles

Amerigo Scientific Releases Automated Liquid Handling Equipment to Modernize Pipetting Workflow

Vast Range of Quantum Dots Available at Alfa Chemistry to Foster Innovations in Biotechnology, Optoelectronics, and Catalysis

PrecisionLife Announces New Appointments to Launch Diagnostics and Healthcare Strategy

PrecisionLife has announced the appointment of Dr Gerald Dunstan as SVP Corporate Development and Hannah Bibby as Product Strategy Lead to drive the company’s expansion into precision diagnostics and personalized healthcare.

This Thanksgiving, Alfa Chemistry Extends Gratitude with Special Offers

BOC Sciences Celebrates Nobel Prize Awarded to Scientists Behind COVID-19 Vaccines

BOC Sciences expressed its congratulations to Katalin Karikó and Drew Weissman for being recipients of the 2023 Nobel Prize in Physiology or Medicine.

Revolutionizing Vaccine Development: Creative Biolabs Leads the Way

With the spotlight on mRNA vaccines post the prestigious Nobel Prize in Physiology or Medicine 2023, Creative Biolabs stands poised to revolutionize this groundbreaking technology.

Yourgene Health Becomes a PacBio Compatible Partner: Enabling PacBio Customers to Optimise Size Selection for Long-Read Sequencing Libraries

Yourgene’s LightBench® instrument offers precise and accurate size selection of PacBio® SMRTbell® sequencing libraries increasing HiFi sequencing yields

CD Formulation Offers a 10% Discount on All Products and Services as Thanksgiving Greetings for 2023

Unleashing the Power of Graphene-Silicon-Carbon Composites: Alfa Chemistry at the Forefront

Alfa Chemistry Helps Partners Achieve mRNA Vaccine Excellence: Development, Production, Optimization, Quality Control

CD Formulation Introduces Powder Flowability Testing to Maximize Tablet Performance

Eremid® Genomic Services partners with Semaphore Solutions to implement cutting-edge Labbit LIMS

Eremid® Genomic Services, LLC ("Eremid"), a CLIA-certified leading-edge genomics CRO, has announced a strategic partnership with Semaphore Solutions, a leader in informatics services and SaaS solutions for the life sciences industry. Eremid will implement Semaphore’s Labbit LIMS across its research, clinical, and training labs, a move that will help take its end-to-end clinical genomics services to the next level and support the development of cutting-edge molecular diagnostics.

Glox Therapeutics Secures £4.3M Seed Funding to Develop Precision Antimicrobials Targeting Drug-resistant Bacteria

• Investment to accelerate development of a novel class of targeted high-potency bacteriocins against specific antimicrobial-resistant pathogens • Spin-out from the Universities of Glasgow and Oxford • Funding led by Boehringer Ingelheim Venture Fund and Scottish Enterprise • Company to establish operations and expand team

Oxford Nanopore and Day Zero Diagnostics Partner to Develop a New Class of Bloodstream Infection Diagnostics

Today, Oxford Nanopore and Day Zero Diagnostics announced a collaboration to develop a new class of diagnostics for bloodstream infections, a leading cause of sepsis. According to the WHO,11 million sepsis-related deaths occur every year—early and effective intervention is key, but current diagnostics require a culture, taking days to get results. Built for use in clinical settings, such as hospitals, the new solution leverages each company’s unique capabilities and will provide same-day identification and genomic-based antibiotic susceptibility profiling without the need for blood culture—so that patients can be prescribed targeted, life-saving treatments sooner. The companies plan to pursue regulatory approvals, including with the FDA, in the future.

Biopharma PEG Elevates ADC Development with Monodispersed PEGs in Versatile Scales

Biopharma PEG introduces monodispersed PEGs, including mPEG36-NH2,NH2-PEG24-COOH, OH-PEG9-OH, mPEG8-SPA , for ADC development at diverse scales. R&D Director highlights their role in modulating ADC properties.

Huateng Pharma Elevates Diabetes Drug Development with High-Purity Anti-Diabetes Intermediates

Huateng Pharma introduces advanced anti-diabetes intermediates, such as Canagliflozin, Dapagliflozin, Empagliflozin, and Semaglutide, representing a major step in diabetes treatment. These high-purity compounds have the potential to revolutionize drug development. Huateng Pharma also offers CDMO services to promote collaboration in the pharmaceutical industry.

Fapon Inaugurates State-of-the-Art R&D Center in Lexington, MA

Fapon is thrilled to announce the grand opening of its US-based Research and Development (R&D) Center, strategically located in Lexington, Massachusetts. This Center represents Fapon’s unwavering commitment to advancing healthcare technologies and will further integrate the company into the local biotechnology ecosystem to accelerate growth.

Medix Biochemica expands its infectious diseases antibody offering through the acquisition of ViroStat

Medix Biochemica has acquired 100 percent of the shares of ViroStat.